What’s Propelling Veracyte Inc (NASDAQ:VCYT) After Lower Shorts Reported?

March 14, 2018 - By Adrian Mccoy

 What’s Propelling Veracyte Inc (NASDAQ:VCYT) After Lower Shorts Reported?

Investors sentiment decreased to 1.76 in 2017 Q3. Its down 0.12, from 1.88 in 2017Q2. It worsened, as 11 investors sold Veracyte, Inc. shares while 14 reduced holdings. 14 funds opened positions while 30 raised stakes. 22.46 million shares or 6.26% more from 21.14 million shares in 2017Q2 were reported.
Moreover, Federated Investors Pa has 0.01% invested in Veracyte, Inc. (NASDAQ:VCYT) for 525,000 shares. Credit Suisse Ag holds 0% or 16,015 shares in its portfolio. State Of Wisconsin Board invested in 0% or 17,000 shares. Axiom Ltd De reported 388,328 shares. The California-based California State Teachers Retirement Systems has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Board Of Trustees Of The Leland Stanford Junior University stated it has 12,500 shares. First Light Asset Ltd Com has invested 2.34% in Veracyte, Inc. (NASDAQ:VCYT). Denver Advsr Limited Com stated it has 0.03% in Veracyte, Inc. (NASDAQ:VCYT). Northern Tru Corporation reported 274,294 shares. Benjamin F Edwards & invested in 270 shares. Goldman Sachs Group Inc accumulated 0% or 29,084 shares. One Trading Ltd Partnership accumulated 3,189 shares. Eventide Asset Mngmt invested in 2.13M shares or 1.06% of the stock. New York State Common Retirement Fund reported 25,200 shares. Renaissance Techs Ltd Liability Company holds 554,759 shares.

Since September 25, 2017, it had 0 insider buys, and 3 sales for $381,180 activity. Hall Christopher M sold $180,000 worth of Veracyte, Inc. (NASDAQ:VCYT) on Monday, October 2.

The stock of Veracyte Inc (NASDAQ:VCYT) registered a decrease of 0.67% in short interest. VCYT’s total short interest was 737,500 shares in March as published by FINRA. Its down 0.67% from 742,500 shares, reported previously. With 131,400 shares average volume, it will take short sellers 6 days to cover their VCYT’s short positions. The short interest to Veracyte Inc’s float is 3.54%.

The stock decreased 2.35% or $0.15 during the last trading session, reaching $6.24. About 71,260 shares traded. Veracyte, Inc. (NASDAQ:VCYT) has risen 56.46% since March 14, 2017 and is uptrending. It has outperformed by 39.76% the S&P500.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $213.98 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Veracyte, Inc. (NASDAQ:VCYT) Ratings Coverage

Among 6 analysts covering Veracyte (NASDAQ:VCYT), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Veracyte had 11 analyst reports since August 14, 2015 according to SRatingsIntel. The stock of Veracyte, Inc. (NASDAQ:VCYT) earned “Outperform” rating by Leerink Swann on Tuesday, November 7. The rating was maintained by BTIG Research on Friday, August 14 with “Buy”. The firm has “Buy” rating given on Friday, December 18 by Cantor Fitzgerald. The stock has “Buy” rating by Janney Capital on Tuesday, November 29. Piper Jaffray maintained it with “Overweight” rating and $12 target in Friday, August 14 report. As per Tuesday, November 7, the company rating was downgraded by Piper Jaffray. The stock of Veracyte, Inc. (NASDAQ:VCYT) earned “Neutral” rating by Janney Capital on Tuesday, November 7.

More news for Veracyte, Inc. (NASDAQ:VCYT) were recently published by: Businesswire.com, which released: “Veracyte Announces New Data Demonstrating “Real-World” Performance of Afirma …” on March 14, 2018. Streetinsider.com‘s article titled: “Form 4 VERACYTE, INC. For: Mar 02 Filed by: Hall Christopher M” and published on March 06, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.